Medical Devices Europe

Europe Automated Insulin Delivery Systems Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Europe Automated Insulin Delivery Systems Market Industry Trends and Forecast to 2034: Segmented by (Component, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $568.1 Mn Placeholder estimate
Estimate 2025 $656.2 Mn 18.4% of the global market
Projected 2034 $2.40 Bn 265.8% Adds $1.74 Bn over 9 forecast years
CAGR 2025–2034 15.5% Faster than 91% of 193 Medical Devices markets here
Key players 6 +1
  • Europe is 18.44% of the global market.
  • Among regions, the largest is North America at $2.00 Bn.
  • Fastest growing: Africa at 18.2% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.74 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Automated Insulin Delivery Systems Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $568.1 Mn — —
2025 (base) $656.2 Mn +$88.1 Mn —
2026 (forecast) $757.9 Mn +$101.7 Mn +15.5%
2027 (forecast) $875.4 Mn +$117.5 Mn +33.4%
2028 (forecast) $1.01 Bn +$135.7 Mn +54.1%
2029 (forecast) $1.17 Bn +$156.7 Mn +78%
2030 (forecast) $1.35 Bn +$181.0 Mn +105.5%
2031 (forecast) $1.56 Bn +$209.1 Mn +137.4%
2032 (forecast) $1.80 Bn +$241.5 Mn +174.2%
2033 (forecast) $2.08 Bn +$278.9 Mn +216.7%
2034 (forecast) $2.40 Bn +$322.1 Mn +265.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe Automated Insulin Delivery Systems Market Analysis at a glance
Market size, 2025$656.2 Mn placeholder estimate
Forecast, 2034$2.40 Bn placeholder estimate
Growth (CAGR), 2025–203415.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsComponent, type and end user (see all)
Key playersMedtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Inc., Abbott Laboratories and 1 more (see all)
Regulator in EuropeEU MDRSource: European Commission, medical devices. Checked 14 Nov 2026.
Active clinical trials152 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe Automated Insulin Delivery Systems Market Analysis Executive Summary

Automated insulin delivery systems link an insulin pump with a glucose sensor and software that adjusts insulin doses automatically.

Key segments of the automated Insulin Delivery Systems market include component (Insulin Pumps, CGM Sensors and Control Algorithms) and type (Hybrid Closed Loop and Advanced Hybrid Closed Loop).

Bar chart: Europe Automated Insulin Delivery Systems market size, 2024–2034, placeholder estimates. $568.1 Mn in 2024, $656.2 Mn in 2025 and $2.40 Bn in 2034, 15.5% CAGR.
Europe Automated Insulin Delivery Systems market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe Automated Insulin Delivery Systems Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the automated Insulin Delivery Systems market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the automated Insulin Delivery Systems market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the automated Insulin Delivery Systems market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Automated Insulin Delivery Systems Market in Europe

The automated Insulin Delivery Systems market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Automated Insulin Delivery Systems Market in Europe

Automated Insulin Delivery Systems in Europe: rules, payment and research

In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first.⁠[1] In the countries we cover here, medical devices are regulated by ANSM (France)⁠[2], BfArM (Germany)⁠[3], Ministry of Health (Italy)⁠[4], Roszdravnadzor (Russia)⁠[5], AEMPS (Spain)⁠[6], MHRA (UK)⁠[7], IGJ (Netherlands)⁠[8], FAMHP (Belgium)⁠[9], Swissmedic (Switzerland)⁠[10], Läkemedelsverket (Sweden)⁠[11], Danish Medicines Agency (Denmark)⁠[12], URPL (Poland)⁠[13] and TITCK (Turkey)⁠[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[15] ClinicalTrials.gov lists 152 studies on Automated Insulin Delivery Systems that are recruiting, active or about to start in Europe.⁠[16]

[1] European Commission, medical devices. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Ministry of Health. Checked 14 Nov 2026.

[5] Roszdravnadzor. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] Health and Youth Care Inspectorate (IGJ). Checked 19 Nov 2026.

[9] Federal Agency for Medicines and Health Products (FAMHP). Checked 19 Nov 2026.

[10] Swissmedic. Checked 19 Nov 2026.

[11] Swedish Medical Products Agency (Läkemedelsverket). Checked 19 Nov 2026.

[12] Danish Medicines Agency. Checked 19 Nov 2026.

[13] Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Checked 19 Nov 2026.

[14] Turkish Medicines and Medical Devices Agency (TITCK). Checked 19 Nov 2026.

[15] European Commission, health technology assessment. Checked 14 Nov 2026.

[16] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how automated Insulin Delivery Systems products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Automated Insulin Delivery Systems right now, from free public sources.

Clinical trials

152 active trials in UK, Germany, France, Italy, Spain, Netherlands, Belgium, Switzerland, Sweden, Denmark, Poland, Turkey and Russia

Recruiting, about to start, or running now. Counted across the 13 countries we report on in Europe.

Top trial sponsors (worldwide)

  1. Sanofi 9 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Eli Lilly and Company 9 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Novo Nordisk A/S 9 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Insulet Corporation 5 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Medtronic 5 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

Diabetes (adults), % of adults (WHO)
CountryValueYear
Belgium6.72022
Denmark2.32022
France2.72022
Germany6.62022
Italy7.22022
Netherlands6.42022
Poland10.82022
Russia8.12022
Spain3.62022
Sweden5.12022
Switzerland4.32022
Turkey16.62022
UK8.82022
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 22 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Automated Insulin Delivery Systems in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Automated Insulin Delivery Systems market in Europe?
Placeholder estimate: about $656.2 Mn in 2025, rising to about $2.40 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Automated Insulin Delivery Systems market in Europe growing?
Placeholder estimate: about 15.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Automated Insulin Delivery Systems market report cover?
The report splits the market by component (Insulin Pumps, CGM Sensors, Control Algorithms), type (Hybrid Closed Loop, Advanced Hybrid Closed Loop) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Automated Insulin Delivery Systems market?
Key players include Medtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Inc., Abbott Laboratories and Beta Bionics.
What is driving the Automated Insulin Delivery Systems market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the automated Insulin Delivery Systems market.
Who regulates Automated Insulin Delivery Systems in Europe?
In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first. Source: European Commission, medical devices. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Automated Insulin Delivery Systems are running in Europe?
152 studies are recruiting, active or about to start in Europe, counted across the 13 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Automated Insulin Delivery Systems?
PubMed lists 373 papers on Automated Insulin Delivery Systems added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Europe

See all

Related on diabetes and remote monitoring and wearables

See the topic